Rituximab and Belimumab Combination Therapy in PR3 Vasculitis

PHASE2UnknownINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

April 30, 2023

Study Completion Date

November 30, 2023

Conditions
ANCA Associated VasculitisGranulomatosis With Polyangiitis
Interventions
DRUG

Belimumab

Sub-cutaneous injection

DRUG

Rituximab

IV infusion 1g x 2

DRUG

Prednisolone

20mg prednisolone tapering dose

Trial Locations (6)

Unknown

Addenbrooke's Hospital, Cambridge

Glasgow Royal Infirmary, Glasgow

Imperial College London, London

Royal Free Hospital, London

Royal Freemann Hospital, Newcastle

Nottingham University Hospitals, Nottingham

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Medical Research Council

OTHER_GOV

collaborator

Imperial College London

OTHER

collaborator

University College, London

OTHER

collaborator

Newcastle University

OTHER

collaborator

University of Glasgow

OTHER

collaborator

University of Cambridge

OTHER

lead

Rachel Jones

OTHER